期刊文献+

非小细胞肺癌术后并发症的危险因素分析 被引量:3

下载PDF
导出
摘要 目的:探讨导致接受肺癌根治术治疗的非小细胞肺癌患者术后并发症发生的危险因素,为临床预防提供参考.方法:选取2013-01/2015-05我院收治的100例行肺癌根治术的非小细胞肺癌患者作为研究对象,所有患者均接受肺癌根治术治疗.回顾性分析所有患者的临床资料,统计术后并发症发生率,并对导致患者术后并发症发生的危险因素进行分析.结果:所有接受肺癌根治术治疗的患者中共有35例发生术后并发症,发生率为35.00%.而经多因素及多因素分析结果显示,年龄>60岁、FEV1%<70%、分期>Ⅱ期、导管留置时间>4 d及住院时间>12 d为导致患者术后发生并发症的危险因素(P<0.05).结论:术后并发症在接受肺癌根治术治疗的非小细胞肺癌患者中仍有较高的发生率,且其可受多种因素的诱发,临床应注意控制危险因素.
作者 冀华逊
出处 《转化医学电子杂志》 2015年第11期68-69,共2页 E-Journal of Translational Medicine
  • 相关文献

参考文献5

二级参考文献236

  • 1杨培基,陈江生,李明.70岁以上老年人肺癌的外科治疗体会[J].中国老年学杂志,2006,26(7):914-915. 被引量:2
  • 2Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002.
  • 3Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-132S, 2004.
  • 4Rosell R, Scagliotti G, Danenberg KD, et al Transcripts in pretreatment biopsies from a threearm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22:3548-3553, 2003.
  • 5Simon G, Sharma A, Li X, et al Feasibility and efficacy of molecular analy- sis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol25:2741-2746, 2007.
  • 6Tibaldi C, Giovannetti E, Vasile E, et al: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797-1803, 2008.
  • 7Dowlati A, Gray R, Sandier AB, et al: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407-1412, 2008.
  • 8Dudek AZ, Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Cancer Invest 23:193-200, 2005.
  • 9Lissoni P, Rovelli F, Malugani F, et al: Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. IntJ Biol Markers 18:152-155, 2003.
  • 10Mihaylova Z, Ludovini V, Gregorg V, et al Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON 12:105-111, 2007.

共引文献152

同被引文献25

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部